Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
1 clinical trials · Condition
◉ Watch Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (NCT04482309) | AstraZeneca | 2020-08-18 |
Track Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer automatically
Every clearance here is in the API, with alerts when new ones post.